Comprehensive Psychiatry
Volume 50, Issue 3 , Pages 245-250 , May 2009

Prevalence of psychotic symptoms in substance users: a comparison across substances

  • Matthew J. Smith

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 312 695 8173l; fax: +1 312 695 6276.
    • ,
  • Jagadisha Thirthalli

      Affiliations

    • Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India
    • ,
  • Arbi Ben Abdallah

      Affiliations

    • Department of Psychiatry, Epidemiology and Prevention Research Group (EPRG), Washington University School of Medicine, St Louis, MO 63101, USA
    • ,
  • Robin M. Murray

      Affiliations

    • Division of Psychiatry and Psychological Medicine, Institute of Psychiatry, London SE5 8AF, United Kingdom
    • ,
  • Linda B. Cottler

      Affiliations

    • Department of Psychiatry, Epidemiology and Prevention Research Group (EPRG), Washington University School of Medicine, St Louis, MO 63101, USA

References 

  1. Mueser KT, Nishith P, Tracy JL, DeGirolamo J, Molinaro M. Expectations and motives for substance use in schizophrenia. Schizophr Bull. 1995;21:367–378
  2. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148:224–230
  3. Boyd JH, Burke JD, Gruenberg E, Holzer CE, Rae DS, George LK, et al. Exclusion criteria of DSM III: a study of co-occurrence of hierarchy-free symptoms. Arch Gen Psychiatry. 1984;41:982–987
  4. Barry K, Fleming M, Greenley L, Kropp S, Widlak P. Characteristics of persons with severe mental illness and substance abuse in rural areas. Psychiatr Serv. 1996;47:88–90
  5. Comtois K, Ries R, Armstrong H. Case manager ratings of the clinical status of dually diagnosed outpatients. Hosp Community Psychiatry. 1994;45:568–573
  6. Lehman AF, Myers C, Corty E, Thompson JW. Prevalence and patterns of “dual diagnosis” among psychiatric inpatients. Compr Psychiatry. 1994;35:106–112
  7. Mueser KT, Yarnold P, Bellack A. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand. 1992;85:48–55
  8. Arseneault L, Cannon M, Poulton R, Murray RM, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212–1213
  9. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. a longitudinal study of Swedish conscripts. Lancet. 1987;26:1483–1486
  10. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev. 2007;27:494–510
  11. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:187–194
  12. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110–117
  13. Wylie AS, Scott RT, Burnett SJ. Psychosis due to “skunk”. BMJ. 1995;311(6997):125
  14. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry. 1974;30:24–27
  15. Talbott JA, Teague JW. Marijuana psychosis. Acute toxic psychosis associated with the use of cannabis derivatives. JAMA. 1969;210:299–302
  16. Connell P. Amphetamine psychosis. Oxford: Oxford University Press; 1958;
  17. Post RM. Cocaine psychoses: a continuum model. Am J Psychiatry. 1975;132:225–231
  18. Farren CK, Hameedi FA, Rosen MA. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend. 2000;59:153–163
  19. Pandurangi AK, Goldberg SC, Brink DD. Amphetamine challenge test. Response to treatment and lateral ventricle size in schizophrenia. Biol Psychiatry. 1989;25:207–214
  20. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572
  21. Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry. 2004;185:298–305
  22. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319–327
  23. Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr Res. 2002;59:77–84
  24. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis. 1990;178:473–480
  25. Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R. A comparison of symptoms and family history of schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res. 2007;93:203–210
  26. Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. 2006;19:239–245
  27. Cottler LB, Compton WM, Price R, Shillington AM, Claverie DJ, Mager DE, et al. St. Louis' Effort to Reduce the Spread of AIDS. In:  Inciardi JA,  Fletcher BW,  Tims F editor. Innovative approaches in the treatment of drug abuse: program models and strategies. USA: Greenwood Press; 1993;p. 205–218
  28. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. In: 3rd ed., Revised. Washington (DC): American Psychiatric Association; 1987;
  29. Cottler LB, Robins LN, Helzer JE. The reliability of the CIDI-SAM: a comprehensive substance abuse interview. Br J Addict. 1989;84:801–814
  30. Cottler LB, Schuckit MA, Helzer JE, Crowley T, Woody G, Nathan P, et al. The DSM-IV field trial for substance use disorders: major results. Drug Alcohol Depend. 1995;38:59–69
  31. Cottler LB, Compton WM. Advantages of the CIDI family of instruments in epidemiological research of substance use disorders. Int J Methods Psychiatr Res. 1993;3:109–119
  32. Horton J, Compton W, Cottler LB. Reliability of substance use disorder diagnoses among African-Americans and Caucasians. Drug Alcohol Depend. 2000;57:203–209
  33. Compton WM, Cottler LB, Dorsey KB, Spitznagel EL, Mager DE. Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. Drug Alcohol Depend. 1996;41:179–187
  34. Compton WM, Thomas YF, Stinson F, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:566–576
  35. McCoy CB, Comerford M, Metsch LR. Employment among chronic drug users at baseline and 6-month follow-up. Subst Use Misuse. 2007;42:1055–1067
  36. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray RM, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry. 2000;57:1053–1058
  37. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022–1031
  38. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237(4819):1219–1223
  39. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ. 2006;332:172–175
  40. Howlett AC, Breivogel CS, Childers CR. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47:345–358
  41. Heikkila RE, Orlansky H, Cohen G. Studies on the distinction between uptake inhibition and release of (3H) dopamine in rat brain tissue slices. Biochem Pharmacol. 1975;24:847–852
  42. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A. 2000;97:6850–6855
  43. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population. Schizophr Res. 2000;45:11–20
  44. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among metamphetamine users. Addiction. 2006;101:1473–1478
  45. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Revised. Washington (DC): American Psychiatric Association; 2000;

PII: S0010-440X(08)00110-7

doi: 10.1016/j.comppsych.2008.07.009

Comprehensive Psychiatry
Volume 50, Issue 3 , Pages 245-250 , May 2009

Article Tools